Asymmetric organocatalytic Michael addition of Meldrum’s acid to nitroalkenes: probing the mechanism of bifunctional thiourea organocatalysts
作者:Ari M.P. Koskinen、Antti O. Kataja
DOI:10.3998/ark.5550190.0011.216
日期:——
The asymmetricMichaeladdition of Meldrum’sacid to nitroalkenes was studied using a novel type of Cinchona alkaloid-based bifunctionalthioureaorganocatalyst. The functionality of the thiourea catalysts was also probed by preparing and testing thiourea-N-methylated analogues of the well-known bis-(3,5-trifluoromethyl)phenyl-substituted catalyst.
The formal total syntheses of (−)-actinophyllic acid and its enantiomer starting from the same chiral intermediate are reported. The synthesis features a photoredox organocatalytic asymmetric alkylation to generate the original C15 chirality, a photocatalytic C–H functionalization of 3-methylindole in flow for constructing the C16 all-carbon quaternary center, a regioselective 1,3-dipolar cycloaddition
combination of CuI and CsOAc was found to catalyze aryl amination under mild conditions. The reaction takes place at room temperature or at 90 °C with broad functional group compatibility. The intramolecular reaction was able to form five-, six-, and seven-membered rings with various protecting groups on the nitrogen atom. The scope of the intermolecular amination, as well as its applications to unsymmetrical
An asymmetric approach to bicyclo[2.2.1]heptane-1-carboxylates via a formal [4 + 2] cycloaddition reaction enabled by organocatalysis
作者:Jian-Guo Fu、Yi-Fan Shan、Wang-Bin Sun、Guo-Qiang Lin、Bing-Feng Sun
DOI:10.1039/c6ob00814c
日期:——
An organocatalytic formal [4 + 2] cycloadditionreaction has been realized that permits rapid access to a wide range of bicyclo[2.2.1]heptane-1-carboxylates in a highly enantioselective manner from simple starting materials under mild and operationally simple conditions.
[EN] AZACARBAZOLE BTK INHIBITORS<br/>[FR] INHIBITEURS DE BTK AZACARBAZOLE
申请人:MERCK SHARP & DOHME
公开号:WO2016164284A1
公开(公告)日:2016-10-13
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein CH, R1, R1a, R1b, R2, R3, and the subscripts m1, m2, p, q, and t are as set forth herein. The present invention also provides pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.